MDT May 2024 47.500 call
| Previous close | 35.50 |
| Open | 35.50 |
| Bid | 30.05 |
| Ask | 34.00 |
| Strike | 47.50 |
| Expiry date | 2024-05-17 |
| Day's range | 35.50 - 35.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
PR NewswireMedtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high density (HD) mapping catheter for the treatment of persistent atrial fibrillation (AFib). The SPHERE Per-AF study, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial, c
- PR Newswire
Late-breaking data show reliable performance of small-diameter defibrillation lead, the Medtronic OmniaSecure™
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that its investigational OmniaSecure™ defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivotal Trial. Late breaking results were presented at Heart Rhythm 2024 and simultaneously published in the journal Heart Rhythm. Worldwide, the OmniaSecure defibrillation lead is investigational
